FDA ac­cepts Iver­ic Bio's NDA, grants pri­or­i­ty re­view for GA drug

On the heels of a sec­ond Phase III win in ge­o­graph­ic at­ro­phy last year, Iver­ic Bio is now wait­ing at the FDA’s doors for its fi­nal de­ci­sion, which is set to come af­ter com­peti­tor Apel­lis Phar­ma­ceu­ti­cals hears from the reg­u­la­tor lat­er this month.

The eye dis­ease-fo­cused biotech an­nounced Thurs­day af­ter­noon the FDA had ac­cept­ed Iver­ic’s NDA for avac­in­cap­tad pe­gol (ACP), a com­ple­ment C5 pro­tein in­hibitor and the biotech’s lead can­di­date. The biotech is seek­ing FDA ap­proval to treat ge­o­graph­ic at­ro­phy (GA) sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD). Ge­o­graph­ic at­ro­phy is a se­vere form of dry AMD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER